For research use only. Not for therapeutic Use.
Faralimomab（Cat No.:M040050）is an investigational monoclonal antibody that targets the protein CD40, a co-stimulatory receptor found on immune cells like B cells and dendritic cells. By activating CD40, faralimomab aims to enhance immune responses against tumors, promoting both innate and adaptive immunity. It is being explored in clinical trials for its potential to treat various cancers, including melanoma and non-small cell lung cancer (NSCLC). Faralimomab is being studied as a single agent and in combination with other therapies to evaluate its safety, efficacy, and ability to boost immune system activity against cancer.
| Catalog Number | M040050 |
| CAS Number | 167816-91-3 |
| Purity | ≥95% |
